Skip to content
value.today
Evogene Ltd. logo

Evogene Ltd.

Evogene Ltd. is listed today as Evogene Ltd.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Evogene Ltd.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2026$3 MPrivate placement after listing$2 to $10 million

Evogene Ltd.: Private sale, Feb 2026

Investors in this round

1 investor had bought by the notice of Feb 19, 2026: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$236,923
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Israel

People named in the notice

  • Gabi Tarcic · Executive Officer · Vice President Product
  • Ilia Zhidkov · Executive Officer · Vice President Computational Platform
  • Ofer Haviv · Executive Officer, Director · President and Chief Executive Officer and Director
  • Yaron Eldad · Executive Officer · Chief Financial Officer
  • Adrian Percy · Director
  • Dan Falk · Director
  • Leon Yehuda Recanati · Director
  • Nir Nimrodi · Director · Chairperson of the Board
  • Sarit Firon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • A.G.P./Alliance Global Partners (CRD 000008361) · New York, New YorkSold in NY

Remarks in the notice

  • On the amounts: “Gross proceeds reflect the cash exercise of 3,384,616 existing warrants at an exercise price of $1.00 per share in a warrant inducement transaction. As part of the inducement, the Company issued new warrants to purchase up to 5,076,924 shares. Gross proce”

Signed by Yaron Eldad, Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 19, 2026. Read the notice at the SEC.

optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Evogene Ltd., its revenue in fiscal 2025 came from these business segments: Industrial application $2.17 million (56%), Agriculture $1.37 million (36%).

    Annual report (SEC XBRL) · Dec 2025

  • Evogene Ltd. chose not to state its revenue in its newest notice of a funding round (Feb 2026).

    SEC Form D · Feb 2026

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Feb 2026

Products and services#

No products or services of Evogene Ltd. are on record.

Investors#

No investor of Evogene Ltd. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding Evogene Ltd. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Evogene Ltd.
NameRoleNamed in
Gabi TarcicVice President ProductFeb 2026
Ilia ZhidkovVice President Computational PlatformFeb 2026
Ofer HavivPresident and Chief Executive Officer and DirectorFeb 2026
Yaron EldadChief Financial OfficerFeb 2026
Adrian PercyDirectorFeb 2026
Dan FalkDirectorFeb 2026
Leon Yehuda RecanatiDirectorFeb 2026
Nir NimrodiChairperson of the BoardFeb 2026
Ofer HavivPresident and Chief Executive Officer and DirectorFeb 2026
Sarit FironDirectorFeb 2026

Went public since 2017. Its SEC number is that of a company listed on a stock exchange.